These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18435748)

  • 1. Antibacterial effect of oregano essential oil alone and in combination with antibiotics against extended-spectrum beta-lactamase-producing Escherichia coli.
    Si H; Hu J; Liu Z; Zeng ZL
    FEMS Immunol Med Microbiol; 2008 Jul; 53(2):190-4. PubMed ID: 18435748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli.
    Puerto AS; Fernández JG; del Castillo Jde D; Pino MJ; Angulo GP
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):135-9. PubMed ID: 16406187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origanum vulgare essential oil: antibacterial activities and synergistic effect with polymyxin B against multidrug-resistant Acinetobacter baumannii.
    Amaral SC; Pruski BB; de Freitas SB; Allend SO; Ferreira MRA; Moreira C; Pereira DIB; Junior ASV; Hartwig DD
    Mol Biol Rep; 2020 Dec; 47(12):9615-9625. PubMed ID: 33190200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran.
    Mehrgan H; Rahbar M
    Int J Antimicrob Agents; 2008 Feb; 31(2):147-51. PubMed ID: 18060745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].
    Noguera O; Rodríguez JC; López JM; Ruiz M; Royo G
    Rev Esp Quimioter; 2009 Mar; 22(1):30-3. PubMed ID: 19308744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in pediatric patients in China].
    Wang L; Yang YH; Lu Q; Wang Y; Chen Y; Deng L; Deng QL; Zhang H; Wang CQ; Liu L; Xu XW; Shen XZ
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1372-5. PubMed ID: 18953872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomegranate pericarp extract enhances the antibacterial activity of ciprofloxacin against extended-spectrum β-lactamase (ESBL) and metallo-β-lactamase (MBL) producing Gram-negative bacilli.
    Dey D; Debnath S; Hazra S; Ghosh S; Ray R; Hazra B
    Food Chem Toxicol; 2012 Dec; 50(12):4302-9. PubMed ID: 22982804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS; García JA; Muñoz JL
    Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia.
    Palasubramaniam S; Muniandy S; Navaratnam P
    J Microbiol Immunol Infect; 2009 Apr; 42(2):129-33. PubMed ID: 19597644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial, mechanical, and barrier properties of cassava starch-chitosan films incorporated with oregano essential oil.
    Pelissari FM; Grossmann MV; Yamashita F; Pineda EA
    J Agric Food Chem; 2009 Aug; 57(16):7499-504. PubMed ID: 19627142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibacterial activities of essential oils from Iranian medicinal plants on extended-spectrum β-lactamase-producing Escherichia coli.
    Sharifi-Rad J; Mnayer D; Roointan A; Shahri F; Ayatollahi SA; Sharifi-Rad M; Molaee N; Sharifi-Rad M
    Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(9):75-82. PubMed ID: 27650980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
    Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
    J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of essential oils and antibiotics reduce antibiotic resistance in plasmid-conferred multidrug resistant bacteria.
    Yap PS; Lim SH; Hu CP; Yiap BC
    Phytomedicine; 2013 Jun; 20(8-9):710-3. PubMed ID: 23537749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of the urinary tract infections due to Escherichia coli harboring extended-spectrum beta lactamase].
    Hori J; Yamaguchi S; Osanai H; Kinebuchi T; Usami K; Takahashi N; Ishii Y
    Hinyokika Kiyo; 2007 Nov; 53(11):777-82. PubMed ID: 18051801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital.
    Koksal F; Ak K; Kucukbasmaci O; Samasti M
    Chemotherapy; 2009; 55(4):293-7. PubMed ID: 19521075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.